CINECA IRIS Institutional Research Information System

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

Prodotti recenti

Deuterium Incorporation Protects Cells from Oxidative Damage

In the cold environments of the interstellar medium, a variety of molecules in which a hydrogen (H) atom has been replaced by its heavier isotope deuterium (D) can be found. From its emergence, life had to counteract the toxic action of many agents, which posed a con...

Quanto del mercato può dirci il suo fallimento

L'attuale diritto fallimentare, di recente radicalmente inciso nei principi e nelle procedure, ha subìto una trasformazione molto repentina rispetto al lento incedere che ha caratterizzato il suo precedente assetto e che ha accompagnato, con poche modifiche sostanziali, i mercanti medievali, ...

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

Plasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. However, the relevance of plasma AR status&#x...

Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer

The possibility that a receptor for androgen is expressed in Breast Cancer (BC) is fascinating given that the tumor is predominantly estrogen-dependent. The androgen receptor (AR) is emerging as a new marker and a potential new therapeutic target in the treatment of BC patients.&#x...

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma ...